Wednesday, March 24, 2021 2:19:00 PM
Kiwi / marjac
It’s an interesting point ... and I develop for the sake of being aware of what may be thrown at us!!
a shareholder is not the company - shareholders have rights separate from the company itself
Sometimes of course the company through its directors take actions which are quite at odds with the interests of shareholders - in the Uk the Companies Act sets out clearly all of these things - I am not sure what governs such matters in USA but I suspect there will be clear parallels
There are times when shareholders can take action against the directors for their actions
So do a group of shareholders here have the ear of the court through Rule 24 application ..I am a little concerned in this sense ... this shareholders group is only recently and loosely formed - it has not entered into detailed communications with the company demanding Rule 60 application nor has it taken action to try and force the company by shareholders at company meetings for example - the group relies on the unanswered letter from one shareholder asking Amarin to take action - is this enough to argue before the court that this group of shareholders took all steps to demand the company act on Rule 60 but the company against the best interests of itsshareholders refused point blank to take any such action and thus the group has no alternative and given the time frames but to bring this action independently of the company ??
I can see some such being put forward
Or -does any of that matter and any party /shareholder can have a go at mixing it in a patent case ??
Marjac is very confident and rightly so he has researched this in detail
But we are as well to always explore what might be coming our way
Alm
It’s an interesting point ... and I develop for the sake of being aware of what may be thrown at us!!
a shareholder is not the company - shareholders have rights separate from the company itself
Sometimes of course the company through its directors take actions which are quite at odds with the interests of shareholders - in the Uk the Companies Act sets out clearly all of these things - I am not sure what governs such matters in USA but I suspect there will be clear parallels
There are times when shareholders can take action against the directors for their actions
So do a group of shareholders here have the ear of the court through Rule 24 application ..I am a little concerned in this sense ... this shareholders group is only recently and loosely formed - it has not entered into detailed communications with the company demanding Rule 60 application nor has it taken action to try and force the company by shareholders at company meetings for example - the group relies on the unanswered letter from one shareholder asking Amarin to take action - is this enough to argue before the court that this group of shareholders took all steps to demand the company act on Rule 60 but the company against the best interests of itsshareholders refused point blank to take any such action and thus the group has no alternative and given the time frames but to bring this action independently of the company ??
I can see some such being put forward
Or -does any of that matter and any party /shareholder can have a go at mixing it in a patent case ??
Marjac is very confident and rightly so he has researched this in detail
But we are as well to always explore what might be coming our way
Alm
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
- New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients • GlobeNewswire Inc. • 11/09/2025 09:15:00 PM
- Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 • GlobeNewswire Inc. • 11/03/2025 01:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2025 08:30:06 PM
